David A. Siegel Supernus Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 8,500 shares of SUPN stock, worth $422,960. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,500

Previous 33,300 74.47%

Holding current value

$422,960

Previous $1.09 Million 75.5%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$30.29 - $33.43 $751,192 - $829,064	-24,800 Reduced 74.47%	8,500 $267,000
Q1 2025 May 15, 2025	BUY	$31.17 - $40.0 $794,835 - $1.02 Million	25,500 Added 326.92%	33,300 $1.09 Million
Q4 2024 Feb 14, 2025	BUY	$31.89 - $37.83 $31,890 - $37,830	1,000 Added 14.71%	7,800 $282,000
Q3 2024 Nov 14, 2024	SELL	$25.77 - $35.16 $613,326 - $836,807	-23,800 Reduced 77.78%	6,800 $212,000
Q2 2024 Aug 14, 2024	SELL	$25.99 - $33.85 $2.93 Million - $3.81 Million	-112,700 Reduced 78.65%	30,600 $818,000
Q1 2024 May 15, 2024	SELL	$27.11 - $35.17 $2.27 Million - $2.95 Million	-83,800 Reduced 36.9%	143,300 $4.89 Million
Q4 2023 Feb 14, 2024	BUY	$22.72 - $29.68 $704,320 - $920,080	31,000 Added 15.81%	227,100 $6.57 Million
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $2.3 Million - $2.74 Million	-83,300 Reduced 29.81%	196,100 $5.41 Million
Q2 2023 Aug 14, 2023	SELL	$29.91 - $38.73 $906,273 - $1.17 Million	-30,300 Reduced 9.78%	279,400 $8.4 Million
Q1 2023 May 15, 2023	BUY	$34.93 - $42.03 $3.27 Million - $3.94 Million	93,700 Added 43.38%	309,700 $11.2 Million
Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $3.69 Million - $4.5 Million	118,700 Added 121.99%	216,000 $7.7 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $2.39 Million - $2.94 Million	83,000 Added 580.42%	97,300 $3.29 Million
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $415,412 - $561,700	-16,400 Reduced 53.42%	14,300 $414,000
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $239,484 - $276,360	8,400 Added 37.67%	30,700 $992,000
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $250,515 - $325,090	9,500 Added 74.22%	22,300 $650,000
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $1.74 Million - $2.32 Million	-74,000 Reduced 85.25%	12,800 $341,000
Q2 2021 Aug 16, 2021	SELL	$26.72 - $33.19 $3.9 Million - $4.85 Million	-146,000 Reduced 62.71%	86,800 $2.67 Million
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $2.16 Million - $2.82 Million	89,600 Added 62.57%	232,800 $6.1 Million
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $1.76 Million - $2.57 Million	-99,500 Reduced 41.0%	143,200 $3.6 Million
Q3 2020 Nov 16, 2020	SELL	$20.2 - $25.05 $3.5 Million - $4.35 Million	-173,500 Reduced 41.69%	242,700 $5.06 Million
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $622,076 - $905,996	36,400 Added 9.58%	416,200 $9.89 Million
Q1 2020 May 15, 2020	BUY	$14.45 - $24.69 $3.62 Million - $6.18 Million	250,200 Added 193.06%	379,800 $6.83 Million
Q4 2019 Feb 14, 2020	SELL	$19.93 - $29.13 $5,979 - $8,739	-300 Reduced 0.23%	129,600 $3.07 Million
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $5.08 Million - $6.65 Million	-199,300 Reduced 60.54%	129,900 $3.57 Million
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $2.91 Million - $3.77 Million	97,000 Added 41.77%	329,200 $10.9 Million
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $7.61 Million - $9.75 Million	232,200 New	232,200 $8.14 Million
Q3 2018 Nov 14, 2018	SELL	$42.7 - $56.55 $495,320 - $655,980	-11,600 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $202,860 - $275,310	4,600 Added 65.71%	11,600 $694,000
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $260,050 - $328,300	7,000 New	7,000 $321,000

Others Institutions Holding SUPN

# of Institutions

313

Shares Held

61.5M

Call Options Held

18.4K

Put Options Held

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.66B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account